A phase I investigation of IL-12 [interleukin-12]/pulse IL-2 [interleukin 2] in adults with advanced solid tumors.

Trial Profile

A phase I investigation of IL-12 [interleukin-12]/pulse IL-2 [interleukin 2] in adults with advanced solid tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Interleukin-12 (Primary) ; Interleukin-2
  • Indications Advanced breast cancer; Lung cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Mar 2017 Status changed from completed to discontinued.
    • 03 Mar 2017 Status changed from completed to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top